Lineage Cell Therapeutics Q2 EPS $(0.03) Beats $(0.04) Estimate, Sales $3.23M Beat $2.20M Estimate
Portfolio Pulse from bharat@benzinga.com
Lineage Cell Therapeutics reported Q2 earnings per share (EPS) of $(0.03), beating the analyst consensus estimate of $(0.04) by 25%. The company also reported quarterly sales of $3.23 million, surpassing the analyst consensus estimate of $2.20 million by 46.59%. However, this represents a 29.17% decrease in sales compared to the same period last year.
August 10, 2023 | 8:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lineage Cell Therapeutics reported better than expected Q2 earnings and sales. However, the company's sales have decreased compared to the same period last year.
Lineage Cell Therapeutics reported better than expected earnings and sales for Q2, which is generally a positive signal for investors and could lead to a short-term increase in the stock price. However, the decrease in sales compared to the same period last year could be a concern for long-term investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100